your badges 52W Range $12–$21 0% of range Analyst Rating SELL 7 analysts Price Target $12 +1% upside P/E -176.4 ROE -6.0% Net Profit Margin -14.6%

AMRN Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range

03
Price $12.35
Market Cap (MRQ) $5.19B
P/E (TTM) -176.4
EPS (TTM) $-0.07
Revenue (TTM) $186M
ROE (TTM) -6.0%
52W Range $12–$21

AMRN Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view

04
range
bars

Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.

Stock splits 3
Ex-date Split Type
April 11, 2025 1-for-20 Reverse
Jan. 18, 2008 1-for-10 Reverse
Oct. 19, 1998 1-for-10 Reverse

About Amarin Corporation plc - American Depositary Shares Company overview from Wikipedia

05 · wikidata

Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid.

In July 2012, their lead-candidate drug named Vascepa (AMR-101) received FDA-approval, competing against GlaxoSmithKline's Lovaza.

History

Amarin Corporation plc (formerly Ethical Holdings plc) was originally incorporated in England as a private limited company on March 1, 1989, and later re-registered as a public company on March 19, 1993. In 2002, the company suffered losses worth $37 million; 2003 losses exceeded $19 million. As of 2005, it was developing neurology drugs. It developed Miraxion to treat serious hereditary neurodegenerative disease.

In December 2007, Amarin acquired Ester Neurosciences Limited for US$8.1 million. In 2011, CEO Joe Zakrzewski said that the company would like to first work on building its infrastructure out to commercialize the drug in the United States.

Products and development

Vascepa (USA) / Vazkepa (EU)

Amarin´s sole product VASCEPA® came on the market in 2013 for triglyceride levels >=500 milligrams per deciliter. In December 2019, the FDA approved "...the use of Vascepa (icosapent ethyl) as an adjunctive (secondary) therapy to reduce the risk of cardiovascular events among adults with elevated triglyceride levels (a type of fat in the blood) of 150 milligrams per deciliter or higher. Patients must also have either established cardiovascular disease or diabetes and two or more additional risk factors for cardiovascular disease....Vascepa is the first FDA approved drug to reduce cardiovascular risk among patients with elevated triglyceride levels as an add-on to maximally tolerated statin therapy.

Furthermore, VASCEPA® is in use in clinical trials by 3rd parties to see, if it has an effect on Alzheimer, Colon Cancer, Nonalcoholic Steatohepatitis (NASH), and other diseases.

HLS Therapeutics, Amarin´s license partner in Canada, presented results of their COVID-19 clinical trial for Vascepa at National Lipid Association Scientific Sessions 2020, December 12. The results demonstrated a 25% reduction of hs-CRP, a biomarker for inflammation. Most people with COVID-19 die, because of a cytokine storm, which causes an uncontrolled and excessive release of pro-inflammatory signaling molecules called cytokines. Two more COVID-19 studies are actually running with Vascepa to validate and proof further benefits.

On January 28, the Committee for Medicinal Products for Human Use gave a positive recommendation for Vazcepa (its name in the EU), which the European Commission finally approved on March 30.

Patent disputes

On March 30, 2020, the designated patent judge in the U.S. District Court for the District of Nevada, Miranda Du, ruled for generic-drug makers Hikma Pharmaceuticals and Dr. Reddy's Laboratories in a lawsuit with Amarin over patents on Amarin's drug, Vascepa. Soon after, on April 2, 2020, Amarin filed an appeal of the ruling. The appeal was lost and an en-banc was also not granted, afterwards. On November 30, three weeks after Hikma Pharmaceuticals started the distribution of their generic version of Vascepa, Amarin filed a complaint of patent infringement against Hikma. On February 11, 2021, Amarin filed a petition for certiorari with the US Supreme Court. On June 21, 2021, the petition was denied.

== Finance ==

Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗

Wikidata ↗

sectorHealthcare industryBiotechnology employees80 countryIE

10-Year Performance Revenue, net income, margins and EPS trends

06
Revenue$214M
2016-12-31 → 2025-12-31
EPS$-0.09
2016-12-31 → 2025-12-31
Free Cash Flow·
2016-12-31 → 2020-12-31
Net margin-14.6%
2016-12-31 → 2025-12-31
Valuation & Ratios 07–12

Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?

Metric 5Y trend AMRN 5Y avg Peer Median Verdict
P/E (TTM) -176.45Y avg ≈591.4 ≈591.4 · ·
P/S (TTM) 27.95Y avg ≈22.7 ≈22.7 · ·
P/B (MRQ) 11.75Y avg ≈11.3 ≈11.3 · ·
Price / Cash Flow 764.05Y avg ≈589.2 ≈589.2 · ·
Price / Tangible Book (MRQ) 12.05Y avg ≈18.7 ≈18.7 · ·

Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.

value · ≈ 5Y avg · industry median · verdict relative to median

Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date

14
Avg Surprise 49.9%
Next Report Oct 27, 2026
PeriodReportEPS ActualEPS EstSurprise
June 30, 2026 Jul 28, 2026 $-0.02 $-0.01 -96.1%
March 31, 2026 $-0.09 $0.09 -203.8%
Dec. 31, 2025 $0.01 $0.00 —
Sept. 30, 2025 $0.08 $-0.58 113.8%
June 30, 2025 $0.66 $-0.18 466.3%
March 31, 2025 $-0.76 $-0.58 -30.7%

Full Fundamentals All metrics by year — income statement, balance sheet, cash flow

15
Income Statement 18
Metric Trend 202520242023202220212020201920182017201620152014
Revenue $214M$229M$307M$369M$583M$614M$430M$229M$181M$130M$82M$54M
Cost of Revenue ····$121M$131M$96M$55M$45M$34M$28M$20M
Gross Profit $121M$81M$166M$242M$462M$483M$334M$175M$136M$96M$54M$34M
R&D Expense $20M$21M$22M$30M$29M$39M$34M$56M$47M$50M$51M$50M
SG&A Expense $115M$152M$200M$304M$408M$463M$324M$227M$135M$111M$101M$79M
Operating Expenses $171M$173M$233M$348M$451M$502M$358M$283M$182M$161M$152M$130M
Operating Income $-50M$-92M$-68M$-106M$11M$-20M$-24M$-108M$-46M$-66M$-98M$-96M
Interest Expense $7.0K$7.0K$8.0K$15.0K$129.0K$3M$7M$9M$10M$19M$20M$19M
Interest Income $11M$13M$12M$3M$1M$5M$8M$1M$429.0K$234.0K$132.0K$96.0K
Other Non-op $3M$1M$2M$-740.0K$-302.0K$104.0K$-75.0K$-326.0K$74.0K$-482.0K$-228.0K$4M
Pretax Income $-36M$-77M$-54M$-104M$11M$-17M$-22M$-116M$-55M$-76M$-118M$-59M
Income Tax $3M$5M$5M$2M$4M$745.0K$164.0K$96.0K$13M$10M$-3M$-3M
Net Income $-39M$-82M$-59M$-106M$8M$-18M$-23M$-116M$-68M$-86M$-115M$-56M
EPS (Basic) $-0.09$-0.20$-0.15$-0.26$0.02$-0.05$-0.07$-0.39$-0.25$-0.41$-0.83$-0.32
EPS (Diluted) $-0.09$-0.20$-0.15$-0.26$0.02$-0.05$-0.07$-0.39$-0.25$-0.41$-0.83$-0.36
Shares (Basic) 414,984,000410,937,000407,655,000401,155,000395,992,000381,759,000342,538,000297,237,000270,652,000211,874,000180,654,000173,719,000
Shares (Diluted) 414,984,000410,937,000407,655,000401,155,000402,480,000381,759,000342,538,000297,237,000270,652,000211,874,000180,654,000173,824,000
EBITDA $-50M$-92M$-68M··$-20M·$-108M$-46M$-66M$-98M$-96M
Balance Sheet 27
Metric Trend 202520242023202220212020201920182017201620152014
Cash & Equivalents $135M$121M$199M$218M$219M$187M$645M$249M$74M$98M$107M$120M
Short-term Investments $168M$173M$121M$92M$235M$314M······
Receivables $127M$122M$134M$131M$164M$155M$116M$67M$45M$20M$14M$8M
Inventory $196M$166M$259M$229M$235M$189M$77M$58M$30M$21M$19M$14M
Prepaid Expense $24M$13M$12M$19M$22M$31M$13M$3M$3M$7M$3M$3M
Other Current Assets ···········$3M
Current Assets $650M$595M$725M$689M$879M$879M$855M$378M$153M$146M$144M$145M
PP&E (Net) $12.0K$16.0K$114.0K$874.0K$1M$2M$2M$63.0K$28.0K$78.0K$243.0K$381.0K
PP&E (Gross) $1M$1M$1M$3M$3M$4M$3M$902.0K$844.0K$821.0K$997.0K$969.0K
Accum. Depreciation $1M$1M$1M$2M$2M$2M$1M$839.0K$816.0K$755.0K$754.0K$588.0K
Intangibles $13M$16M$19M$22M$24M$14M$15M$7M$8M$9M$9M$10M
Other Non-current Assets $1M$1M$1M$458.0K$456.0K$432.0K$1M$174.0K$174.0K$741.0K$174.0K$3M
Total Assets $671M$685M$832M$886M$1.07B$966M$882M$386M$162M$167M$173M$171M
Accounts Payable $45M$40M$53M$65M$115M$106M$50M$38M$25M$6M$11M$9M
Current Liabilities $194M$180M$259M$259M$371M$307M$242M$157M$109M$76M$51M$40M
Capital Leases $6M$8M$9M$10M$9M$9M$9M·····
Other Non-current Liabilities $11M$12M$9M$8M$8M$6M$4M$11M$1M$710.0K$335.0K$386.0K
Total Liabilities $211M$199M$280M$291M$401M$339M$274M$233M$227M$176M$301M$260M
Long-term Debt ······$50M$80M$92M$94M$92M$105M
Total Debt ·····$0·$80M$93M$101M$106M$105M
Common Stock $310M$305M$303M$299M$294M$290M$269M$247M$209M$207M$150M$143M
Paid-in Capital $1.92B$1.91B$1.90B$1.89B$1.86B$1.82B$1.76B$1.28B$978M···
Retained Earnings $-1.71B$-1.67B$-1.59B$-1.53B$-1.42B$-1.43B$-1.41B$-1.39B$-1.27B$-1.20B$-1.12B$-970M
Treasury Stock $67M$65M$64M$62M$61M$51M$36M$10M$4M$1M$411.0K$217.0K
Stockholders' Equity $459M$486M$552M$595M$667M$628M$608M$152M$-65M$-9M$-129M$-88M
Liabilities + Equity $671M$685M$832M$886M$1.07B$966M$882M$386M$162M$167M$173M$171M
Shares Outstanding 416,214,102411,584,851408,824,093408,824,093396,598,008392,538,081360,103,901325,850,013271,022,011269,363,696183,403,263174,590,372
Cash Flow 17
Metric Trend 202520242023202220212020201920182017201620152014
D&A ·······$23.0K$62.0K$138.0K$166.0K$198.0K
Stock-based Comp $14M$18M$16M$26M$37M$46M$31M$19M$14M$14M$14M$9M
Deferred Tax ········$11M$9M$-4M$-4M
Amort. of Intangibles $3M$3M$3M$3M$2M$1M$679.0K$646.0K$646.0K$645.0K$646.0K$646.0K
Restructuring $36M$0$11M$14M$14M·······
Operating Cash Flow $7M$-31M$7M$-180M$-67M$-22M$-9M$-95M$-33M$-72M$-84M$-75M
CapEx ·····$252.0K$2M$58.0K$12.0K$21.0K$28.0K·
Investing Cash Flow $9M$-46M$-26M$175M$104M$-377M$-2M$-58.0K$-12.0K$-21.0K··
Net Debt Issued ·····$-50M·$-15M$-3M···
Stock Issued ······$440M$265M·$65M··
Stock Repurchased ··········$194.0K·
Net Stock Activity ·······$265M·$65M$-194.0K·
Financing Cash Flow $-2M$-1M$230.0K$-379.0K$-5M$-59M$410M$271M$8M$63M··
Net Change in Cash $14M$-78M$-18M$-5M$32M$-458M$398M$176M$-25M$-9M$-13M$-72M
Taxes Paid $1M$4M$2M$-2M$4M$-207.0K$-67.0K·····
Free Cash Flow ·····$-22M·$-95M$-33M$-72M$-85M·
Levered FCF ·····$-25M·$-104M$-45M$-93M$-104M·
Profitability 8
Metric Trend 202520242023202220212020201920182017201620152014
Gross Margin 56.6%35.6%53.9%··78.6%·76.2%75.2%73.6%65.9%62.2%
Operating Margin -23.5%-40.2%-22.0%··-3.2%·-47.2%-25.1%-50.4%-120.1%-177.0%
Net Margin -18.2%-35.9%-19.3%··-2.9%·-50.8%-37.5%-66.4%-140.9%-104.0%
Pretax Margin -16.9%-33.8%-17.5%··-2.8%·-50.8%-30.3%-58.7%-144.7%-109.2%
EBITDA Margin -23.5%-40.2%-22.0%··-3.2%·-47.2%-25.1%-50.4%-120.1%-177.0%
ROA -5.7%-10.8%-6.9%··-1.9%·-42.5%-41.3%-50.8%-66.9%-26.6%
ROE -8.4%-16.2%-10.7%··-2.9%·-234.1%183.0%124.9%105.9%92.2%
ROIC -11.8%-20.1%-13.5%··-3.3%·-46.6%-200.8%-80.6%417.0%-551.6%
Liquidity & Solvency 5
Metric Trend 202520242023202220212020201920182017201620152014
Current Ratio 3.33.32.8··2.9·2.41.41.92.83.6
Quick Ratio 2.22.31.8··2.1·2.01.11.62.43.2
Debt / Equity ·····0.0·0.5-1.4-11.2-0.8-1.2
LT Debt / Equity ·······0.3-1.1-9.4-0.7-1.0
Interest Coverage -7167.1-13113.9-8448.5··-7.5·-12.2-4.7-3.5-4.9-5.2
Efficiency 3
Metric Trend 202520242023202220212020201920182017201620152014
Asset Turnover 0.30.30.4··0.7·0.81.10.80.50.3
Inventory Turnover ·····1.0·1.21.81.71.71.2
Receivables Turnover 1.71.82.3··4.5·4.15.57.77.59.4
Per Share 5
Metric Trend 202520242023202220212020201920182017201620152014
Book Value / Share $1.10$1.18$1.35··$1.60·$0.47$-0.24$-0.03$-0.70$-0.51
Revenue / Share $0.51$0.56$0.75··$1.61·$0.77$0.67$0.61$0.45$0.31
Cash Flow / Share $0.02$-0.08$0.02··$-0.06·$-0.32$-0.12$-0.34$-0.47$-0.42
Cash / Share $0.32$0.29$0.49··$0.48·$0.76$0.27$0.36$0.58$0.68
EPS (TTM) $-0.09$-0.20$-0.15$-0.26$0.02$-0.05$-0.07$-0.39$-0.25$-0.41$-0.83$-0.36
Growth Rates 3
Metric Trend 202520242023202220212020201920182017201620152014
Revenue YoY -6.6%-25.5%-16.9%-36.7%-5.0%·······
Revenue CAGR 3Y -16.7%-26.8%-20.6%·········
Revenue CAGR 5Y -19.0%···········
Valuation (TTM) 14
Metric Trend 202520242023202220212020201920182017201620152014
Revenue TTM $214M$229M$307M$369M$583M$614M$430M$229M$181M$130M$82M$54M
Net Income TTM $-39M$-82M$-59M$-106M$8M$-18M$-23M$-116M$-68M$-86M$-115M$-56M
Market Cap $5.81B$4.03B$7.11B··$38.39B·$88.70B$21.74B$16.59B$6.93B$3.42B
Enterprise Value ·····$37.89B·$88.53B$21.76B$16.60B$6.93B$3.41B
P/E -155.1-49.0-116.0-93.13370.0-1956.0-6125.7-697.9-320.8-150.2-45.5-54.4
P/S 27.217.623.2··62.5·387.0120.0127.684.863.1
P/B 12.78.312.9··61.2·582.3-333.9-1831.8-53.7-38.7
P / Tangible Book 13.08.613.417.141.562.6······
P / Cash Flow 863.6-130.01033.9··-1765.4·-936.6-661.9-231.0-81.8-47.3
P / FCF ·····-1745.2·-936.0-661.7-231.0-81.8·
EV / EBITDA ·····-1927.7·-818.0-477.6-252.9-70.6-35.5
EV / FCF ·····-1722.4·-934.2-662.3-231.0-81.8·
EV / Revenue ·····61.7·386.2120.1127.684.862.9
Earnings Yield -0.64%-2.0%-0.86%-1.1%0.03%-0.05%-0.02%-0.14%-0.31%-0.67%-2.2%-1.8%

Most recent period on the left · null values shown as ·

Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years

16
Metric 2025-12-312024-12-312023-12-312022-12-312021-12-31
Revenue $214M $229M $307M $369M $583M
Gross Margin % 56.6% 35.6% 53.9% · ·
Operating Margin % -23.5% -40.2% -22.0% · ·
Net Income $-39M $-82M $-59M $-106M $8M
Diluted EPS $-0.09 $-0.20 $-0.15 $-0.26 $0.02

Institutional owners (13F) 88 filers · $64.3M total · As of June 30, 2026

17

Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.

Holders 88
Value held $64.3M
New positions 21
Exited positions 7
Institutional activity — Q2 2026 vs prior quarter
New positions Exited positions Increased Decreased Net shares change
21 (+13 vs prior Q) 7 (-12 vs prior Q) 16 (-3 vs prior Q) 14 (-1 vs prior Q) +79K

Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.

Institution Value Shares % of tracked 13F Type
Sarissa Capital Management LP $26,673,916 1,673,395 41.49% Shares
Kynam Capital Management, LP $8,495,733 532,982 13.22% Shares
MORGAN STANLEY $3,564,456 223,617 5.54% Shares
Waterfront Wealth Inc. $3,183,561 213,949 4.95% Shares
Brooklands Fund Management Ltd $2,741,449 177,325 4.26% Shares
Eversept Partners, LP $2,316,018 145,296 3.60% Shares
MILLENNIUM MANAGEMENT LLC $1,845,980 115,808 2.87% Shares
TWO SIGMA INVESTMENTS, LP $1,602,145 100,511 2.49% Shares
CITADEL ADVISORS LLC $1,520,103 95,364 2.36% Shares
BNP PARIBAS FINANCIAL MARKETS $1,144,699 71,813 1.78% Shares
LCM Capital Management Inc $818,710 51,362 1.27% Shares
RENAISSANCE TECHNOLOGIES LLC $771,002 48,369 1.20% Shares
SUSQUEHANNA INTERNATIONAL GROUP, LLP $765,120 48,000 1.19% Call option
JANE STREET GROUP, LLC $599,790 37,628 0.93% Shares
George Kaiser Family Foundation $593,080 37,207 0.92% Shares
TWO SIGMA ADVISERS, LP $516,265 36,995 0.80% Shares
SEI INVESTMENTS CO $465,628 29,211 0.72% Shares
SUSQUEHANNA INTERNATIONAL GROUP, LLP $462,276 29,001 0.72% Shares
STATE STREET CORP $398,755 25,016 0.62% Shares
SUSQUEHANNA INTERNATIONAL GROUP, LLP $385,748 24,200 0.60% Put option
Bleakley Financial Group, LLC $374,670 23,505 0.58% Shares
AMERIPRISE FINANCIAL INC $302,573 18,982 0.47% Shares
State of New Jersey Common Pension Fund D $300,931 18,879 0.47% Shares
CITADEL ADVISORS LLC $299,672 18,800 0.47% Put option
COMMONWEALTH OF PENNSYLVANIA PUBLIC SCHOOL EMPLS RETRMT SYS $292,818 18,370 0.46% Shares
RAYMOND JAMES FINANCIAL INC $289,550 18,165 0.45% Shares
R Squared Ltd $269,992 16,938 0.42% Shares
State of Tennessee, Department of Treasury $239,164 15,004 0.37% Shares
Quadrature Capital Ltd $236,581 14,842 0.37% Shares
Quinn Opportunity Partners LLC $228,022 14,305 0.35% Shares
Cubist Systematic Strategies, LLC $224,390 13,699 0.35% Shares
WELLS FARGO & COMPANY/MN $221,773 13,913 0.34% Shares
EntryPoint Capital, LLC $194,882 12,226 0.30% Shares
Jump Financial, LLC $191,407 12,008 0.30% Shares
GEODE CAPITAL MANAGEMENT, LLC $187,629 11,771 0.29% Shares
OSAIC HOLDINGS, INC. $184,333 11,565 0.29% Shares
NJ State Employees Deferred Compensation Plan $178,542 10,900 0.28% Shares
Verdad Advisers, LP $166,270 10,431 0.26% Shares
CITADEL ADVISORS LLC $164,182 10,300 0.26% Call option
UBS Group AG $160,404 10,063 0.25% Shares
Steward Partners Investment Advisory, LLC $142,025 8,910 0.22% Shares
NEW YORK STATE COMMON RETIREMENT FUND $121,224 7,605 0.19% Shares
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO $92,038 5,774 0.14% Shares
Federation des caisses Desjardins du Quebec $73,518 4,615 0.11% Shares
RHUMBLINE ADVISERS $59,498 3,733 0.09% Shares
NATIONAL BANK OF CANADA /FI/ $40,137 2,518 0.06% Shares
ROYAL BANK OF CANADA $30,000 1,877 0.05% Shares
GAMMA Investing LLC $25,121 1,576 0.04% Shares
NewEdge Advisors, LLC $21,471 1,347 0.03% Shares
Farther Finance Advisors, LLC $15,271 958 0.02% Shares

Show all 88 institutional owners →

Activists & 5%+ owners 35 positions

18

Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.

Filer Filed Stake Status Purpose Filing
Alexander J Denner, Sarissa Capital Management LP Aug. 27, 2026 6.09% Amendment · SEC
Sarissa Capital Management LP, Alexander J Denner ×3 filings March 25, 2025 8.08% Amendment Board campaign SEC
Feb. 28, 2023 · Initial filing · SEC
Feb. 27, 2023 · Initial filing · SEC
Feb. 21, 2023 · Initial filing · SEC
OR ×6 filings Feb. 15, 2023 · Initial filing · SEC
Feb. 14, 2023 · Initial filing · SEC
Feb. 10, 2023 · Initial filing · SEC
Jan. 19, 2023 · Initial filing · SEC
June 16, 2022 · Initial filing · SEC
Sofinnova Venture Partners VII, L.P. (“SVP VII”), Sofinnova Management VII, L.L.C. (“SM VII”), Dr. Michael F. Powell (“Powell”), Dr. James I. Healy (“Healy”), Eric P. Buatois (“Buatois”) ×4 filings Aug. 23, 2013 · Initial filing Passive investment SEC
Abingworth LLP 98-051-8585, Abingworth Bioventures V Co-Invest Growth Equity Fund LP 98-057-9772, Abingworth Bioventures V L.P. 98-051-8587, Abingworth Bioequities Master Fund Limited 66-066-0960 ×10 filings July 22, 2013 · Initial filing Board campaign SEC
Boxer Capital, LLC, Boxer Asset Management Inc., Joseph Lewis ×4 filings Aug. 24, 2011 · Initial filing · SEC
OrbiMed Advisors LLC, OrbiMed Capital GP III LLC, Samuel D. Isaly ×14 filings April 28, 2011 · Initial filing · SEC
Fountain Healthcare Partners Fund 1, L.P. (“ Fountain ”), Fountain Healthcare Partners Ltd., Manus Rogan, Aidan King, Ena Prosser, Justin Lynch ×2 filings Dec. 10, 2010 · Initial filing · SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Company insiders 43 insiders · 18 officers · 27 directors

19
Insider Role Last activity Shares owned Buys 12m Sells 12m Net 12m
Aaron Berg President and CEO June 26, 2026 M 85,648 0 0 $0
Patrick Holt President and CEO Jan. 22, 2024 P 314,426 0 0 $0
Karim Mikhail President and CEO Feb. 21, 2023 A 283,507 0 0 $0
John F Thero President and CEO July 30, 2021 M 3,252,752 0 0 $0
Peter L. Fishman SVP, CFO Aug. 1, 2026 A 7,619 0 0 $0
Thomas Charles Reilly EVP and CFO July 1, 2024 M 94,305 0 0 $0
Michael Wayne Kalb SVP and CFO July 29, 2022 M 337,314 0 0 $0
David Paul Keenan EVP, Chief Operating Officer July 1, 2026 A 13,470 0 0 $0
Jonathan Provoost EVP, Chief Legal Officer July 1, 2026 A 4,624 0 0 $0
Steven B Ketchum EVP, Chief Scientific Officer July 1, 2026 A 42,680 0 0 $0
Jason M. Marks EVP,Chief Global Legal Officer Aug. 19, 2022 M 21,917 0 0 $0
Joseph T Kennedy General Counsel July 30, 2021 M 317,860 0 0 $0
Mark Salyer Chief Commercial Officer Feb. 1, 2018 A · 0 0 $0
Michael James Farrell VP, Finance Feb. 1, 2016 A 30,190 0 0 $0
Paul Huff Chief Commercial Officer July 26, 2012 A 0 0 0 $0
Stuart D Sedlack Senior Vice President July 26, 2012 A 0 0 0 $0
Paresh Soni SVP and Head of Development Feb. 1, 2012 A 0 0 0 $0
Frederick W Ahlholm Vice President Finance Feb. 1, 2012 A 0 0 0 $0
Oliver O'Connor Director April 18, 2026 M 801 0 0 $0
Paul Cohen Director April 18, 2026 M 836 0 0 $0
Diane E. Sullivan Director April 18, 2026 M 836 0 0 $0
Louis Sterling III Director April 18, 2026 M 4,049 0 0 $0
Patrice Eadon Bonfiglio Director April 18, 2026 M 836 0 0 $0
Keith Horn Director April 18, 2026 M 836 0 0 $0
Odysseas D Kostas Director April 18, 2026 M 836 0 0 $0
Mark Dipaolo Director April 18, 2025 M 401 0 0 $0
Olsen Per Wold Director Jan. 10, 2023 M 171,027 0 0 $0
Murray Stewart Director Jan. 9, 2023 A · 0 0 $0
Adam Mark Berger Director Oct. 20, 2022 A · 0 0 $0
Geraldine Murphy Director Oct. 20, 2022 A · 0 0 $0
Alfonso G Zulueta Director June 27, 2022 A · 0 0 $0
Erin S. Enright Director June 27, 2022 A · 0 0 $0
Kristine Peterson Director June 27, 2022 A 0 0 0 $0
Patrick J O'Sullivan Director June 27, 2022 A · 0 0 $0
Lars Ekman Director June 27, 2022 A 0 0 0 $0
VAN HEEK G JAN Director June 27, 2022 A 14,168 0 0 $0
Joseph S Zakrzewski Director Dec. 15, 2021 P 196,547 0 0 $0
David M Stack Director June 14, 2021 A 40,000 0 0 $0
Dr. James I. Healy Director July 11, 2016 A 90,000 0 0 $0
GORDON CARL L Director Sept. 4, 2012 S 5,700 0 0 $0
Joseph Anderson Director July 10, 2012 A 11,683 0 0 $0
David W Feigal Jr Director July 12, 2011 A · 0 0 $0
Abingworth LLP 10% owner April 19, 2012 S 1,599,168 0 0 $0

Insiders from SEC Form 3/4/5 filings; net = open-market P/S only

AMRN Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside

21
rating · 7 analysts SELL
Median target $12.50 +1.2%
0 0.0% Strong Buy
0 0.0% Buy
2 28.6% Hold
3 42.9% Sell
2 28.6% Strong Sell

12-Month Price Target

2 analysts · 2026-10-03

Mean target $12.50 +1.2%

Now Current price $12.35
Low$12.00 Mean$12.50 High$13.00

Peer comparison (GICS sub-industry) Key metrics vs sector peers

22

FY basis, prices as of each company's last fiscal year-end close.

Ticker Market Cap P/E Rev YoY Net Margin ROE Gross Margin
AMRN $5.81B -155.1 -6.6% -18.2% -8.4% 56.6%
ALKS $4.63B 19.6 -5.2% 16.4% 14.0% ·
PRTA $514M -2.1 -92.8% -2520.6% -63.6% ·

My Metrics Your personal watchlist — selected rows from Full Fundamentals

26

Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.

Your selection is saved and follows you across all tickers.

Source: SEC 10-Q filed Jul 29, 2026